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Objective: To evaluate the budget impact and the direct costs of the introduction of
subcutaneous belimumab (SC) into the Spanish National Health Service (NHS) for patients
with systemic lupus erythematosus (SLE) in Spain.
Methods: This study was conducted from the Spanish NHS perspective with a time horizon
of 3 years. The budget impact analysis compared the cost difference between two scenarios:
current market (standard therapy (ST) and intravenous belimumab (IV)) and other market in
which patients switched from belimumab IV to belimumab SC until reaching 17% of the
total market share. The eligible population was calculated to receive treatment with belimu-
mab, applying the EPISER (study of the prevalence of rheumatic diseases in adult population
in Spain) prevalence (91 per 100,000 inhabitants), Autoimmune Systemic Diseases Study
Group (GEAS) incidence (2 per 100,000 inhabitants), and the risk of annual mortality to the
Spanish adult population. Patients with severe active lupus nephritis and with severe active
CNS lupus were excluded. Patients’ characteristics, flare rates and severity, and healthcare
resource consumption were evaluated based on data from the literature and interviews with
an expert panel. A sensitivity analysis was performed.
Results: Currently, there is an estimated 34,697 adult patients with SLE in Spain and 3849
patients who are eligible to be treated with belimumab. The introduction of belimumab SC
into the Spanish NHS could generate savings in direct healthcare costs of 6 million euros
over the 3 years.
Conclusion: The introduction of belimumab SC shows direct savings for the Spanish NHS.
These savings could contribute to sustainability and decision-making.
Keywords: belimumab, budget impact, Spanish National Health Service, NHS, Systemic
Lupus Erythematosus
Introduction
Systemic lupus erythematosus (SLE) is a severe autoimmune disease which can affect
multiple organs1 and which presents different clinical manifestations.2 It can affect any
organ or system, with joints, kidneys, and the skin the most commonly affected areas.3
Most patients have a relapsing and remitting clinical course in the form of flares or
exacerbations interspersed with periods of inactivity. These flares can lead mainly to
irreversible alterations of vital organs,1 which may affect the survival rate of patients
with SLE.2 Likewise, SLE negatively impacts patient quality of life.4
The complexity of this disease and the time it takes before the appearance of
severe symptoms make it difficult to make an early diagnosis in patients with SLE.5
Correspondence: Josefina Cortés-
Hernández
Department of Internal Medicine, Vall
d’Hebron Institut de Recerca (VHIR), Vall
d’Hebron University Hospital Research





ClinicoEconomics and Outcomes Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com ClinicoEconomics and Outcomes Research 2019:11 757–765 757
http://doi.org/10.2147/CEOR.S218464
DovePress © 2019 Cevey et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For








































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
A study carried out in Germany showed that it is possible
to reduce the time until the first rheumatology appointment
by making doctors and the health system aware of the
seriousness of this disease. This would result in better
management of the patient and disease activity, as well
as a reduction in the healthcare resources and benefit
patients to continue to work.5 Early diagnosis, disease
control, and adjustment of therapies according to the
treat to target concept are important in avoiding severe
flares and irreversible organ damage and can maintain the
patient in a state of remission or low disease activity.6 The
SLE clinical practice guidelines from the Ministry of
Health, Social Services and Equality,1 the Spanish
Society of Rheumatology (SER),7 and the Spanish
Society of Internal Medicine (SEMI)8 agree that the
main objective of the drug therapy for patients with SLE
is to avoid flares of disease in order to prevent irreversible
organ damage.
The Systemic LUpus Erythematosus Cost of Care In
Europe Study (LUCIE) on the burden of SLE illness
carried out in 5 European countries, including Spain, con-
cluded that inadequate management of SLE activity pro-
duces an increase in severe flares; this entails an increase
in the associated costs, mainly in hospital admissions.9 In
the retrospective study reviewing medical records across 5
hospitals in Spain, the healthcare resources associated with
the managing and treating SLE and its flares, and the
associated direct cost, were studied from a Spanish NHS
perspective. We included adult patients with SLE (ACR
criteria) with positive autoantibodies, receiving medical
treatment and with active disease. The patients were clas-
sified into severe and not severe. Severe patients were
defined as having at least one major domain involved at
inclusion (renal, neurological, cardiovascular, or respira-
tory) and requiring prednisone equivalent dosages >7.5
mg/day and/or immunosuppressants. Patients’ disease
activity and severity were assessed at baseline. In this
study, only direct costs were included: laboratory and
diagnostic tests, drug therapies, specialist visits, and hos-
pital admissions. Despite treatment, management of dis-
ease activity was inadequate in the majority of patients,
with 90.7% presenting at least one flare during a two-year
follow-up period. The major component of the healthcare
cost related to hospital admissions, which constituted
44.8% of the total cost. It was found that the average
annual direct cost associated with the management of
SLE was €4833 per patient. The cost associated with the
treatment and management of patients with severe disease
(€5968) was significantly higher than that of non-severe
patients (€3604) (p = 0.003).10 This cost may have been
higher if the social perspective had been taken into
account in the study. A study showed that 36% of the
employed patients with SLE and 40% of those with rheu-
matoid arthritis had had at least one period of sick leave
during the past 12 months.11
The budget impact has become a significant pharma-
coeconomic element in decision-making. It allows us to
estimate the financial viability of introducing new technol-
ogies, providing very useful information for healthcare
decision-makers.12 The objective of this study was to
estimate the budget impact of incorporating belimumab
SC within the Spanish National Health Service (NHS) as
an adjuvant treatment for SLE in adult patients with posi-
tive autoantibodies and high disease activity in Spain.
Patients with severe active lupus nephritis or severe active
Central Nervous System (CNS) lupus were excluded.
Materials And Methods
A budget impact model was developed from the perspec-
tive of the Spanish NHS. Direct health costs: pharmacolo-
gical treatments, administration, and management of flares
were evaluated. The costs were estimated for a time hor-
izon of 3 years (2018 to 2020) without applying a discount
rate, as indicated in the international guidelines.11 Indirect
costs were not included.
The model was completed with data from published litera-
ture, official publications, market research data, and through a
questionnaire conducted with a panel of experts comprising
specialists in Rheumatology and Internal Medicine, which
addressed those assumptions where data were not available.
In addition, the panel of experts also validated the data used.
This study was funded by GlaxoSmithKline and the panel of
experts were not blinded about the study.
The budget impact model compared the cost difference
in each year in two scenarios: a current market scenario:
standard therapy and belimumab IV without belimumab
SC; and a new market scenario: in which the patients
switched from belimumab IV to belimumab SC until
reaching approximately 17% of the market share. The
assumption of the proportion of patients in both scenarios
according to their distribution in the different drug thera-
pies over the 3-year horizon was made taking into account
the company’s internal data, market research, and assess-
ment by the expert panel. The following distribution of
patients was assumed as a percentage in the different
scenarios:
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● Current scenario: belimumab IV + standard therapy
(22.8% in year 1, 23.7% in year 2, 23.2% in year 3)
and standard therapy (77.2% in year 1, 76.3% in the
year 2, 76.8% in year 3).
● New scenario: belimumab SC + standard therapy
(7.5% in year 1, 14.5% in year 2, 16.8% in year 3);
belimumab IV + standard therapy (15.3% in year 1,
9.2% in year 2, 6.4% in year 3) and standard therapy
(77.2% in year 1, 76.3% in year 2, 76.8% in year 3).
Population Eligible For Treatment With
Belimumab
The estimated eligible population to receive belimumab
treatment was calculated from the general population of
adults in Spain (≥18 years), according to data from the
National Institute of Statistics.13 Epidemiological data on
the prevalence of SLE from the EPISER epidemiological
study (91 per 100,000 inhabitants) were applied,14 of which
88% of the cases are diagnosed.15 Based on the study by
Somers et al16 and the Spanish study by Rúa-Figueroa et al17
32% of the SLE population was excluded due to suffering
from severe active lupus nephritis or severe active Central
Nervous System (CNS) lupus, as set out in Summary Product
of Characteristics.18 Likewise, only 59% of the population
had positive autoantibody tests (99% based on ANA) and
active disease.19 Finally, we identified the subgroup of
patients with high disease activity despite standard therapy
(35%)9 and who are on pharmacological treatment (90%).14
In order to estimate the direct cost offsets related to
belimumab SC, a pharmacoeconomic study was conducted.
This model was developed in Excel 2010 and complies with
the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR)12 best practice guidelines.
In the model, the annual incidence of SLE (2 per 100,000
population-year) from the GEAS group20 and the adjusted
Spanish mortality21 for patients with SLE were taken into
account. In order to estimate the mortality, the SLE specific
mortality risk fromBultink22 for patients under 40 years (RR:
4.87) and from the Bernatsky study23 for the other patients
(between 40 and 59 years RR: 3.5 and for 60 years or more
RR: 1.5) was applied to the all-cause mortality risk in Spain.
The age distribution of the Spanish Rheumatology Society
SLE Registry (RELESSER-T) study was used.24 The risk of
annual mortality of patients with SLE for Spain is 0.129% for
patients <40 years, 0.635% for patients of 40–59 years, and
5.484% for patients of ≥60 years.
The pharmacoeconomic model assumed that in the first
year the prevalence includes the mortality and the new
cases of the first 6 months. For this reason, the incidence
of the first year would be half that of subsequent years.
Treatments And Costs
Annual treatment costs of different pharmacological treat-
ments were calculated using the ex-factory price.25
According to Summary Product of Characteristics, the
recommended dose of belimumab IV is 10 mg/kg on days 0,
14, and 28, and then at 4-week intervals.26 Therefore, in the
first year, the patient receives 15 administrations and from
the second year receives 13 administrations. As Benlysta IV
depends on weight, the average weight (69 kg) of the Study
of Belimumab Subcutaneous in Subjects with SLE trial
[BLISS-SC] was used as a reference for calculating annual
treatment cost.27
According to Summary Product of Characteristics, the
recommended dose of belimumab SC is 200 mg once a
week, administered subcutaneously and the dosage is not
based on weight.28 We estimate 52 administrations per year.
The standard therapy, according to the Clinical Practice
Guidelines from the Ministry of Health, Social Services and
Equality1 and the distribution allocated by the panel of
experts, encompassed 83% corticosteroids, 83% anti-malar-
ials, 52% non-biological immunosuppressants (non-biolo-
gical immunosuppressants: methotrexate, intravenous
cyclophosphamide, leflunomide, azathioprine, cyclospor-
ine, and mycophenolate), 20%NSAIDs, 13% other biologic
immunosuppressants used off-label such as rituximab, 2%
intravenous immunoglobulins, and 0.07% plasmapheresis.
Drug cost price was based on ex-factory price.25 Taking into
account, the weight of SLE patients (69 kg)26 and the body
surface area (1.8 m2),29 in necessary cases, and the rate of
plasma exchange,30–32 the average annual treatment cost
calculated of standard therapy was €1034.71. Doses of
different pharmacological treatments were validated by
the expert panel. In the case of standard therapy adminis-
tered with belimumab SC and IV, the average annual treat-
ment cost calculated of standard therapy was €438.42,
because it did not include other biologic treatments.
Estimated Cost Of Administration
The cost of administration of intravenous treatments was
calculated using administration hospital fees (€260.67).32–40
The average cost calculated for standard therapy
administration was €205.62 per patient. However, the
average cost of standard therapy administration when it
Dovepress Cevey et al
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was administered together with belimumab SC and IV was
€103.96 per patient, because it did not include other bio-
logic treatments.
Estimated Costs Of Managing Severe And
Non-Severe Flares
The number of flares per treatment was estimated based on
changes in the SELENA-SLEDAI score, changes in the
signs or symptoms of disease activity, changes in predni-
sone dose, use of new drugs due to disease activity, and
changes in the physician’s global assessment (PGA). Non-
severe flares were defined as flares triggered by an
increase of ≥3 in the SELENA-SLEDAI score. Serious
flares were defined as flares triggered by an increase of
>12 in SELENA-SLEDAI score or a flare requiring hos-
pital admission. Considering that the efficacy of belimu-
mab SC and IV is equivalent,41 the same number of severe
and non-severe flares was used for both formulations of
belimumab. Adding belimumab to standard therapy
showed an average of 2.15 non-severe flares per year,
while standard therapy alone showed an annual average
of 2.5 non-severe flares. Likewise, adding belimumab to
standard therapy showed an annual average of 0.54 severe
flares compared to 1.01 with standard therapy alone.42
To calculate the cost of management severe flares, the
average cost of hospital admission for connective tissue
disorder with complications was assumed at €4840.29/
event.43 This cost was based on DRG (Diagnosis Related
Groups) 240: Connective tissue disorders with complica-
tions that group patients according to admission for a
connective tissue disease such as SLE, rheumatoid arthri-
tis, amyloidosis, juvenile rheumatoid arthritis, etc. To cal-
culate the cost of management non-severe flares was
assumed: a visit to the specialist (€92.54), a laboratory
test (€68.32)43–49,50 and that 10% of the patients required
hospital admission, applied to the average cost of DRG
241: Connective tissue disorders without complications
(€386.26/event).42 This means the cost of treating a non-
severe flare was €547.12.
Sensitivity Analysis
Taking into account that economic models have a certain
level of uncertainty associated with the assumptions made,
in this budget impact analysis a sensitivity analysis was
carried out using a tornado diagram to assess the robust-
ness of the results. The various assumptions were the
percentage of patients with high disease activity, the
percentage of patients with positive autoantibodies and
active disease, the percentage of patients without severe
active lupus nephritis or severe active CNS lupus, the
percentage of patients treated, weight, the percentage of
patients diagnosed, the percentage of patients according to
age, and relative risk of mortality. These assumptions were
validated and agreed with the panel of experts.
Results
It is currently estimated that there are 34,697 adult patients
with SLE, 88% (30,533) of whom have been diagnosed. A
total of 20,610 of these are patients without severe active
lupus nephritis or severe active CNS lupus, decreasing to
around 3849 patients with positive autoantibodies and high
disease activity on pharmacological treatment (Table 1).
The 3-year projection for this subgroup of patients with
SLE with positive autoantibodies and high disease activity
is 3891 patients in the first year, 3943 in the second year,
and 3995 in the third year, assuming an average annual
incidence of 85 patients and an annual mortality of 33
patients.
Direct Costs
The annual cost of treatment with belimumab SC was
€11,902.80 per patient. The annual cost of treatment with
belimumab IV was €12,448.28 per patient on ongoing
phase (13 administrations per year) and €14,363.40 per
patient on loading phase (15 administrations per year).
Likewise, the annual cost of administration calculated
for treatment with belimumab IV was €3388.72 per patient
on ongoing phase and €3910.07 per patient on loading
phase.
Table 2 shows the annual costs per patient associated
with flares according to severity and the direct savings
associated with flares treated with belimumab. Treatment
with belimumab shows an annual reduction in the cost of
non-severe and severe flares per patient versus standard
therapy of €2444.48.
Budget Impact Analysis
The total budget impact of introducing belimumab SC
treatment in the Spanish NHS for adult patients with
SLE with positive autoantibodies and high disease activity
despite standard treatment was calculated as the cost dif-
ference between the current scenario and the new scenario.
Direct health costs were considered in order to calculate
total budget impact: pharmacological treatments, adminis-
tration, and management of flares. The introduction of
Cevey et al Dovepress
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belimumab SC into the Spanish NHS could generate sav-
ings in direct healthcare costs of €6,038,803 over the 3
years. The results are shown in Figure 1.
Pharmacological budget impact was calculated, con-
sidering only pharmacological costs. The introduction of
belimumab SC within the Spanish NHS could generate
savings of €863,193.20 over the 3 years. The results of
pharmacological budget impact are shown in Table 3. This
saving comes from the lower annual treatment cost of
belimumab SC compared to belimumab IV on loading or
ongoing phase.
Sensitivity Analysis
The sensitivity analysis confirmed the estimated savings to
the Spanish NHS, due to the introduction of belimumab
SC to the pharmacological treatments available for treating
adult patients with SLE. This cost saving ranges between 3
and 7 million euros for the total budget impact (Figure 2).
Discussion
The introduction of belimumab SC shows relevant savings for
the Spanish NHS in the 3-year period studied. The results of
this study show that direct healthcare costs were lower in
patients treated with belimumab SC compared to those treated
with belimumab IV. This new subcutaneous formulation will
not only reduce the direct costs derived from its administration
and acquisition but it will also be able to free-up healthcare
facilities mainly in day hospitals, to the benefit of patients and
healthcare professionals. In addition, subcutaneous adminis-
tration is a less invasive treatment than intravenous adminis-
tration and has a reduced administration time of only a few
minutes. It can be a self-administered treatment.
Taking into account that belimumab SC is administered as
a weekly fixed-dose regimen of 200 mg regardless of patient
weight, there will therefore be a predictable budget impact.
The introduction of belimumab SC into the Spanish
NHS could, in its first 3 years of commercialization, gen-
erate a saving of approximately 800 thousand euros in
pharmacological costs, and a total saving of direct health
costs of 6 million euros.
SLE is a chronic, serious condition that affects patients of
working age. Given that the disease occurs in women with an
average age of 38 years,51 there are also significant indirect
costs associated with SLE. A real clinical practice study con-
ducted in Spain evaluated variables of healthcare resource
consumption and absence from work, after 6 months of treat-
ment with IV belimumab in patients with SLE. The patients
treated with belimumab IV presented a reduction in the use of
healthcare resources directly related to the management of the
disease, such as the use of corticosteroids, as well as a sub-
stantial reduction in the days of absence from work.52
Additionally, the subcutaneous formulation will offer greater
comfort and ease of administration, reducing absence from
work as the drug may be administered outside the hospital and
Table 1 Estimated Adult Population With SLE With High Disease Activity And Positive Autoantibodies In Spain
N References
Spanish adult population 38,128,226 National Institute of Statistics (INE) 201713
Population with SLE 34,697 EPISER14 and systemic auto-immune disease (GEAS) group
Diagnosed with SLE 30,533 Expert panel15
SLE population without severe active lupus nephritis or severe active
CNS lupus
20,610 Adapted from: Somers EC et al 200916 and Rúa-Figueroa I
et al 201417
SLE population with positive autoantibodies and disease activity 12,220 Lupus Monitor19
SLE population with high disease activity 4277 Adapted from Cervera et al 201310
On pharmacological treatment 3849 Expert panel15
Table 2 Annual Costs Per Patient Associated With Flares According To Severity
Treatment Cost Of Non-Severe Flares Cost Of Severe Flares
Belimumab SC + Standard Therapy €1172.41 €2640.22
Belimumab IV + Standard Therapy €1172.41 €2640.22
Standard Therapy €1367.81 €4889.30
Reduction in annual costs €195.40 €2249.08
Total reduction in annual costs €2,444.48
Dovepress Cevey et al
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even offers an option for patients in whom it is difficult to
access veins for injection.
It should also be noted that this disease has associated
direct costs derived from clinical management, highlight-
ing the recurrent hospital admissions of patients mainly
due to flares and associated organ damage. The LUCIE
study showed that the major component of the health cost
corresponded to hospital admissions.9 Patients treated with
belimumab in addition to standard therapy showed a
reduced average number of flares per year compared to
patients treated with standard therapy alone.42
The use of belimumab is recommended in different
national clinical guidelines: clinical practice guide on
SLE from the Ministry of Health, Social Services and
Equality1 clinical practice guide of the Study Group of
Autoimmune Diseases (GEAS) of the Spanish Society of
Internal Medicine (SEMI)19 and the Consensus of the
Spanish Society of Rheumatology (SER) on the use of
biological therapies in SLE.6
To carry out this study and develop the budget impact
model, the same efficacy has been set out for both formula-
tions. In a network meta-analysis with the objective of estab-
lishing the comparability of both formulations of belimumab
IV and SC in patients with SLE, it was demonstrated that in
patients with high disease activity, the efficacy of the SC
formulation was comparable to that of the IV formulation.53
40.30 €
41.27 € 41.57 €
39.15 € 39.02 € 38.93 €
-1.15 €
















Scenario without belimumab SC Scenario with belimumab SC Net Impact
Figure 1 Total budget impact of the introduction of belimumab SC in the Spanish NHS.
Table 3 Pharmacological Budget Impact Of The Introduction Of Belimumab SC
Year 1 Year 2 Year 3
Total number of patients eligible for belimumab 3891 3943 3995
Total patients on belimumab treatment 889 (22.8%) 934 (23.7%) 927 (23.2%)
Scenario without belimumab SC
Belimumab IV + ST €11,002,596.27 €11,568,022.00 €11,481,887.90
Standard Therapy €1,693,285.12 €1,716,054.31 €1,738,631.99
Total €12,695,881.38 €13,284,076.31 €13,220,519.90
Scenario with belimumab SC
Belimumab SC + ST €3,452,758.06 €6,763,692.63 €7,932,655.42
Belimumab IV + ST €7,385,521.46 €4,482,603.39 €3,172,082.01
Standard Therapy €1,693,285.12 €1,716,054.31 €1,738,631.99
Total €12,531,564.63 €12,962,350.33 €12,843,369.43
Net Impact - €164,316.75 - €321,725.98 - €377,150.47
Abbreviation: ST, standard therapy.
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This means that both formulations have the same costs in
terms of disease management, but with different administra-
tion and pharmacological direct costs.
Belimumab has been shown to have a positive effect
on the quality of life of patients, both in the physical
component and in the vitality domain of the SF-36 and
in the fatigue score (FACIT-Fatigue).54 These clinically
significant improvements are consistent with the reduction
of disease activity. Therefore, the use of belimumab in
patients with positive autoantibodies and high disease
activity despite standard therapy may offer benefits both
economically and clinically.
Study Limitations
Our study is not free from the limitations inherent to esti-
mating the budget impact made using models. However, the
information with the most available evidence has been used.
Also, the data have been validated by a panel of clinical
experts with real experience in the management and treat-
ment of patients with SLE in Spain.
It should be noted that the estimated number of patients
being treated who will eventually receive SC belimumab is
obviously speculative, and may depend on various aspects,
including the low prevalence of the disease, the detection of
positive autoantibodies, as well as the clinical criteria and the
difficulty in accessing all patients who received treatment.
However, the estimated number of patients receiving treatment
comes from the EPISER study,13 which was conducted more
than a decade ago, and the results may be outdated. For this
reason, the Spanish Society of Rheumatology has re-launched
the study55 and, therefore, our results could be affected by the
new estimate. In addition, it would be advisable to have long-
term epidemiological studies in the future that allow the rele-
vance of SLE to be demonstrated with real data, both at a
clinical and economic level, thus better contextualising the
consequences of the disease.
Conclusions
This study provides pharmacoeconomic information that
can aid in decision-making related to the prescription of
treatments for patients with SLE. The introduction of
belimumab SC demonstrates direct savings for the
Spanish NHS. This decrease in direct costs will allow a
better management of Spanish NHS resources, contribut-
ing to its sustainability. This is a study based on estimates
and assumptions about future impact. Further develop-
ments could be possible to demonstrate the real impact
in a retrospective study.
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